Clinical trial · no report yet · Phase 3
MOUNTAINEER-03
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- NCT05253651 ↗
- Recruiting
- Seagen, a wholly owned subsidiary of Pfizer
- 19 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 9 | |
| Podcasts | 8 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Colorectal Neoplasms
- Interventions
- tucatinib; trastuzumab; bevacizumab; cetuximab; oxaliplatin; leucovorin; levoleucovorin; fluorouracil
- Arms
- Tucatinib Arm · Experimental
- Standard of Care Arm · Active comparator
- Enrollment
- 400 (estimated)
- Primary outcomes
- Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR)
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Start
- Oct 24, 2022
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05253651 · updated Jul 22, 2026
Publications
linked from the registry- Strickler JH, Bekaii-Saab T, Cercek A, Heinemann V, Nakamura Y, Raghav K, Siena S, Tabernero J, Van Cutsem E, Yoshino T, Ramos J, Guan X, Andre T. MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncol. 2025 Feb;21(3):303-311. doi: 10.1080/14796694.2024.2441101. Epub 2024 Dec 26. PubMed 39723627